BioSpace News Archive

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Adial’s Chief Executive Officer will participate in a fireside chat at the 2022 Virtual Growth Conference.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), announced today that Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer, will present a “Spotlight Showcase” of Synaptogenix under the title “Regenerative Therapeutics” on Tuesday, March 22nd at 8am ET.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management Post-Traumatic Stress Disorder, Central Nervous System disorders and anti-viral indications, completed all FDA required pre-clinical studies for Epoladerm™, Virpax’s investigational pre-filled topical spray analgesic product to manage chronic pain associated with osteoarthritis (OA) of the knee.

Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced record financial results for the fourth quarter and full year of 2021.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed a 24-month product stability study required by the U.S. Food and Drug Administration (FDA) for its clinical trial product candidate, CypCaps™

CanSino Biologics Inc. announced that its Recombinant Novel Coronavirus Vaccine has been approved by the Ministry of Health Malaysia and the Indonesian National Agency of Drug and Food Control as a heterologous booster.

Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS™).

CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, announced today that it will showcase the new CurvaFix® IM Implant at the American Academy of Orthopaedic Surgeon’s (AAOS) 2022 Annual Meeting in Chicago.

Statera Biopharma, Inc. announced the pricing of its underwritten public offering of approximately 10,843,721 units, at a price to the public of $0.45 per Unit and approximately 1,716,666 pre-funded units, at a price to the public of $0.44 per Pre-Funded Unit, for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses.